Department of Emergency, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Bioengineered. 2021 Dec;12(1):2890-2905. doi: 10.1080/21655979.2021.1937906.
Acute myocardial infarction (AMI) was considered a fatal disease resulting in high morbidity and mortality; platelet activation or aggregation plays a critical role in participating in the pathogenesis of AMI. The current study aimed to reveal the underlying mechanisms of platelets in the confrontation of AMI and potential biomarkers that separate AMI from other cardiovascular diseases and healthy people with bioinformatic strategies. Immunity analysis revealed that the neutrophil was significantly decreased in patients with SCAD compared with patients with ST-segment elevation myocardial infarction (STEMI) or healthy controls; monocytes and neutrophils showed potential in distinguishing patients with STEMI from patients with SCAD. Six differentially expressed genes (DEGs) showed great performances in differentiating STEMI patients from SCAD patients with AUC greater than 0.9. Correlation analysis showed that these six DEGs were significantly positively correlated with neutrophils; three genes were negatively correlated with monocytes. Weighted gene co-expression network analysis (WGCNA) found that module 'royalblue' had the highest correlation with STEMI; genes in STEMI-related module were enriched in cell-cell interactions, blood vessels' biological processes, and peroxisome proliferator-activated receptor (PPAR) signaling pathway; four genes (, and ) represented the capability of identifying patients with STEMI from healthy controls and patients with SCAD; two genes ( and ) were considered as novel biomarkers for identifying STEMI from SCAD; represented the potential as a novel biomarker for STEMI. Our findings indicated that the distribution of neutrophils could be considered as a potential molecular trait for separating patients with STEMI from SCAD.
急性心肌梗死(AMI)曾被认为是一种致命疾病,导致高发病率和死亡率;血小板激活或聚集在参与 AMI 的发病机制中起着关键作用。本研究旨在通过生物信息学策略揭示血小板在对抗 AMI 中的潜在机制和潜在生物标志物,以将 AMI 与其他心血管疾病和健康人群区分开来。免疫分析显示,与 ST 段抬高型心肌梗死(STEMI)或健康对照组患者相比,SCAD 患者中性粒细胞显著减少;单核细胞和中性粒细胞具有区分 STEMI 患者和 SCAD 患者的潜力。六个差异表达基因(DEGs)在区分 STEMI 患者和 SCAD 患者方面表现出色,AUC 大于 0.9。相关性分析表明,这六个 DEGs 与中性粒细胞呈显著正相关;三个基因与单核细胞呈负相关。加权基因共表达网络分析(WGCNA)发现,模块“royalblue”与 STEMI 相关性最高;与 STEMI 相关的模块中的基因富集在细胞-细胞相互作用、血管的生物学过程和过氧化物酶体增殖物激活受体(PPAR)信号通路中;四个基因(、和)代表了从健康对照组和 SCAD 患者中识别 STEMI 患者的能力;两个基因(和)被认为是识别 STEMI 与 SCAD 的新型生物标志物;代表了作为 STEMI 新型生物标志物的潜力。我们的研究结果表明,中性粒细胞的分布可以被认为是区分 STEMI 患者和 SCAD 患者的潜在分子特征。